Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B

Cancer

Volumn 82, Issue 8, 1998, Pages 1578-1584

  Samuels, Brian L ^a,i   Herndon II, James E ^b   Harmon, David C ^c   Carey, Robert ^c   Aisner, Joseph ^d   Corson, Joseph M ^e   Suzuki, Yasunosuke ^f   Green, Mark R ^g   Vogelzang, Nicholas J ^h  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b CALGB Statistical Center   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MOUNT SINAI HOSPITAL   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

ⁱ Lutheran General Cancer Center   (United States)

Author keywords

Cisplatin; Dihydro 5 azacytidine; Medical oncology; Mesothelioma; Phase II study

Indexed keywords

5,6 DIHYDROAZACITIDINE; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; NAUSEA; PERICARDIAL DISEASE; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; THORAX PAIN; THROMBOSIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CHEST PAIN; CISPLATIN; FEMALE; HUMANS; LEUKOPENIA; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0032522949     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1578::AID-CNCR21>3.0.CO;2-0     Document Type: Article

References (34)

1. Mossman B, Gee J. Asbestos-related diseases. N Engl J Med 1989;320:1721-30.
2. Rogers A, Leigh J, Berry G, Ferguson A, Mulder H, Ackad M. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma: a case control study. Cancer 1991;67:1912-20.
3. Gibbs A, Griffiths D, Pooley F, Jones J. Comparison of fiber types and size distributions in lung tissues of paraoccupational and occupational cases of malignant mesothelioma. Br J Ind Med 1990;47:621-6.
4. Kishimoto T, Okada K, Sato T, Ono T, Ito H. Evaluation of the pleural malignant mesothelioma patients with the relation of asbestos exposure. Environ Res 1989;48:42-8.
5. Da Valle M, Faber L, Kittle C, Jensik R. Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Ann Thorac Surg 1986;42:612-8.
6. Faber L. Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Ann Thorac Surg 1994;58:1782-3.
7. Rusch V, Piantadosi S, Holmes E. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9.
8. Ong S, Vogelzang N. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-17.
9. Alberts A, Falkson G, Goedhals L, Vorobiof D, Van der Merwe C. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35.
10. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1994;107:3325-3445.
11. Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Cotre P, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990;8:151-4.
12. Chahinian A, Antman K, Goutsou M, Corson J, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-65.
13. Vogelzang N, Goutsou M, Corson J, Suzuki Y, Graziano S, Aisner J, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990;27:239-42.
14. Solheim O, Saeter G, Finnanger A, Stenwig A. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992;65:956-60.
15. Vogelzang N, Weissman L, Herndon J, Antman K, Cooper M, Corson J, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study. J Clin Oncol 1994;12:1436-42.
16. Belani C, Herndon J, Vogelzang N, Green M. Edatrexate with oral leucovorin rescue for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 1995;14:352.
17. Belani C, Herndon J, Vogelzang N, Green M. Edatrexate for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 1994;13:329.
18. Dihydro-5-azacytidine hydrochloride (DHAC, NSC 264880) [clinical brochure, Cancer Therapy Evaluation Program edition]. Bethesda, MD: National Cancer Institute, 1981.
19. Voytek P, Beisler J, Abbasi M, Wolpert-Defilipes M. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydroazacytidine. Cancer Res 1977; 37:1956-61.
20. Traganos F, Staiano-Coico L, Darzynkiewicz Z, Melamed M. Effects of dihydro-5-azacytidine on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res 1977;41:780-9.
21. Beisler J, Abbasi M, Driscoll J. Dihydro-5-azacytidine hydrochloride: a biologically active and chemically stable analog of 5-azacytidine. Cancer Treat Rep 1974;60:1671-4.
22. Curt G, Kelly J, Fine R, Huguenin P, Roth J, Batist G, et al. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). Cancer Res 1985;45:3359-63.
23. Carr B, Rahbar S, Doroshow J. Fetal hemoglobin gene activation in a phase I study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Res 1987;47:4199-201.
24. Harmon D, Vogelzang N, Roboz J, Goutsou M, Antman K, Coughlin K, et al. Dihydro-5-azacytidine (DHAC) in malignant mesothelioma using serum hyaluronic acid as a tumor marker: a phase II trial of the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 1991;10:351.
25. Samuels B, Green M, Harmon D, Aisner J, Herndon J, Mason-Coughlin K, et al. Dihydro-5-azacytidine (DHAC) and cisplatin (DDP) in malignant mesothelioma. Proc Am Soc Clin Oncol 1994;11:1470.
26. Weiss R, Vogelzang N, Peterson B, Panasci L, Carpenter J, Gavigan M, et al. A successful system of scientific data audits for clinical trials. J Am Med Assoc 1993;270:459-64.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
28. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients: the Dana Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
29. Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre A, Rembeaux A, et al. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988; 93:159-62.
30. Herndon JE, Green MR, Chahinian P, Belani C, Samuels BL, Weissman L, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 1996;15:1413.
31. Lanphear B, Buncher C. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-21.
32. Conley B, Van Echo D. Antineoplastic drug development. In: M. Perry, editor. The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 1992:15-21.
33. Vogelzang N. Malignant mesothelioma:diagnostic and management strategies for 1992. Semin Oncol 1992; 19:64-71.
34. Anand A, Anand A, Anand N. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1996;77:1959-60.